NEW YORK (TheStreet) -- RATINGS CHANGES
Ambit Biosciences (AMBI) was initiated with a sell rating at TheStreet Ratings.
C.R. Bard (BCR) was downgraded at Barclays to equal weight from overweight. Pressure on company due to its exposure to the peripheral vascular space, which is affected by Medtronic (MDT) - Get Report/Covidien (COV) deal, Barclays said.
Franklin Resources (BEN) - Get Report was upgraded at Goldman Sachs to buy from neutral. Better flow trends are being driven by emerging markets, and recent underperformance offers a cheap entry point, Goldman said.
Medtronic was upgraded at Barclays to overweight from equal weight. Driven by potential benefits from acquisition of Covidien, Barclays said. Twelve-month price target is $73.
[Read: Here Are 2014's Most Union-Friendly Cars]
Tyson Foods (TSN) - Get Report upgraded at BMO Capital to outperform. Higher margins create opportunities for realized earnings potential in Hillshire and accelerated repaying of debts, BMO Capital said. Twelve-month price target is $43.
Walgreen (WAG) was upgraded at Barclays to overweight from equal weight. Driven by reducing expenses and optimizing capital structure, Barclays said. Twelve-month price target is $92.
Editor's note: To see analysts' stock comments and changes to price targets and earnings estimates, go to "Street Notes" which is available only to Real Money subscribers. To find out how to become a subscriber, please click here.
This article was written by a staff member of TheStreet.